List of Tables
Table 1: Top Countries with COVID-19 Key Stats
List of Figures
Figure 1: Impact of COVID-19
Figure 2: Top Countries in COVID-19 Key Stats
Figure 3: Landscape of Pipeline Candidates for COVID-19, by Phase
Figure 4: Landscape of Vaccines Candidates for COVID-19, by Phase
Figure 5: Number of COVID-19 Clinical Trials by Start Date, by Month
Figure 6: Number of COVID-19 Clinical Trials, by Multinational vs. Single Country
Figure 7: Single Country COVID-19 Clinical Trials, By Region & Phase
Figure 8: Multinational Country COVID-19 Clinical Trials, By Region & Phase
Figure 9: COVID-19 Clinical Trial Sites, by Region
Figures 10 & 11: COVID-19 Clinical Trial Sites, by Country & State
Figures 12 & 13: Number of COVID-19 Clinical Trials, by Phase & Status
Figure 14: Endpoint Status for Completed COVID-19 Clinical Trials
Figure 15: Top Reasons for Terminated Trials, by Phase
Figure 16: Top Reason for Terminated Trials, by Sponsor Type
Figure 17: COVID-19 Clinical Trials by Vaccine, by Month
Figures 18 & 19: Vaccine COVID-19 Clinical Trials, by Phase & Status
Figure 20: Vaccine COVID-19 Clinical Trials, by Sponsor Type
Figure 21: Top Industry Sponsors for COVID-19 Vaccine Clinical Trials
Figure 22: Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials
Figures 23 & 24: Pfizer/BioNTech’s Tozinameran (Comirnaty), by Status & Phase
Figures 25 & 26: Moderna’s mRNA-1273, by Status & Phase
Figures 27 & 28: Johnson & Johnson’s JNJ-78436735, by Status & Phase
Figures 29 & 30: AstraZeneca’s Covishield (Vaxzevria), by Status & Phase
Figures 31 & 32: Bharat Biotech’s Covaxin, by Status & Phase
Figures 33 & 34: CanSino Biologics’ Convidecia, by Status & Phase
Figures 35 & 36: SinoVac Biotech’s CoronaVac, by Status & Phase
Figure 37: Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines
Figure 38: Clinical Trial Start Date to First Approval for Vaccines
Figure 39: COVID-19 Therapeutic Clinical Trials, by Month
Figure 40 & 41: Therapeutic COVID-19 Clinical Trials, by Phase & Status
Figure 42: Therapeutic COVID-19 Clinical Trials, by Sponsor Type
Figure 43: Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials
Figure 44: Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials
Figures 45 & 46: Gilead Sciences’ Remdesivir (Veklury), by Status & Phase
Figures 47 & 48: Fujifim Toyama Chemical’s Favipiravir, by Status & Phase
Figures 49 & 50: Eli Lilly’s Bamlanivimab, by Status & Phase
Figures 51 & 52: Regeneron’s Casirivimab + Imdevimab, by Status & Phase
Figures 53 & 54: Eli Lilly’s Baricitinib, by Status & Phase
Figures 55 & 56: CytoDyn’s Leronlimab, by Status & Phase
Figure 57: Upcoming Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs
Figure 58: Clinical Trials Disrupted Due to COVID-19
Figures 59 & 60: Disrupted Clinical Trials, by Reason
Figure 61 & 62: Disrupted Clinical Trials, by Therapy Area
Figure 63: Disrupted Clinical Trials Activities
Figure 64: Disrupted Clinical Trials, by Top Sponsors
Figure 65: Resumed Clinical Trials, by Top Five Therapy Areas
